Evidence map›Paper›PMID 35775429›Full record

ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2022

Rapidly adapting primary care sentinel surveillance across seven countries in Europe for COVID-19 in the first half of 2020: strengths, challenges, and lessons learned.

Jayshree Bagaria, Tessa Jansen, Diogo Fp Marques, Mariette Hooiveld, Jim McMenamin, Simon de Lusignan, Ana-Maria Vilcu, Adam Meijer, Ana-Paula Rodrigues, Mia Brytting and 8 more

Abstract read
In one paragraph

Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Article
  3. Primary care sentinel surveillance of influenza-like illness and laboratory detections of respiratory viral infections in Denmark, week 40 2021 to week 39 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025
    Article
  4. Evaluation of European severe acute respiratory infection (SARI) surveillance, 27 European countries, 2022/23.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025
    Article
  5. Article
  6. Trends in human parainfluenza virus in Scotland before and after the peak of the COVID-19 pandemic, January 2017 to October 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025
    Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Monitoring COVID-19 and Influenza: The Added Value of a Severe Acute Respiratory Infection Surveillance System in Portugal.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2023
    Article
  18. Using the rear-view mirror to look forward.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023
    Article
  19. Antiviral Peptides as Anti-Influenza Agents.International journal of molecular sciences · 2022
    Review
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Jayshree BagariaPublic Health Scotland, Glasgow, Scotland.
Tessa JansenNivel, Utrecht, The Netherlands.
Diogo Fp MarquesEpiconcept, Paris, France.
Mariette HooiveldNivel, Utrecht, The Netherlands.
Jim McMenaminPublic Health Scotland, Glasgow, Scotland.
Simon de LusignanNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.
Ana-Maria VilcuINSERM, Sorbonne Université, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France.
Adam MeijerNational Institute for Public Health and the Environment, Bilthoven, the Netherlands.
Ana-Paula RodriguesInstituto Nacional de Saúde Dr. Ricardo Jorge, Lisbon, Portugal.
Mia BryttingThe Public Health Agency of Sweden, Stockholm, Sweden.
Clara MazagatosNational Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain.
Jade CogdaleHealth Security Agency, London, United Kingdom.
Sylvie van der WerfInstitut Pasteur, Université Paris Cité, CNRS UMR 3569, Molecular Genetics of RNA viruses unit, National Reference Center for Respiratory Viruses, Paris, France.
Frederika DijkstraNational Institute for Public Health and the Environment, Bilthoven, the Netherlands.
Raquel GuiomarInstituto Nacional de Saúde Dr. Ricardo Jorge, Lisbon, Portugal.
Theresa EnkirchThe Public Health Agency of Sweden, Stockholm, Sweden.
Marta ValencianoEpiconcept, Paris, France.
I-MOVE-COVID-19 study teamThe members of the I-MOVE-COVID-19 primary care study team are listed under Collaborators.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As the COVID-19 pandemic began in early 2020, primary care influenza sentinel surveillance networks within the Influenza - Monitoring Vaccine Effectiveness in Europe (I-MOVE) consortium rapidly adapted to COVID-19 surveillance. This study maps system adaptations and lessons learned about aligning influenza and COVID-19 surveillance following ECDC / WHO/Europe recommendations and preparing for other diseases possibly emerging in the future. Using a qualitative approach, we describe the adaptations of seven sentinel sites in five European Union countries and the United Kingdom during the first pandemic phase (March-September 2020). Adaptations to sentinel systems were substantial (2/7 sites), moderate (2/7) or minor (3/7 sites). Most adaptations encompassed patient referral and sample collection pathways, laboratory testing and data collection. Strengths included established networks of primary care providers, highly qualified testing laboratories and stakeholder commitments. One challenge was the decreasing number of samples due to altered patient pathways. Lessons learned included flexibility establishing new routines and new laboratory testing. To enable simultaneous sentinel surveillance of influenza and COVID-19, experiences of the sentinel sites and testing infrastructure should be considered. The contradicting aims of rapid case finding and contact tracing, which are needed for control during a pandemic and regular surveillance, should be carefully balanced.

Indexed as

COVID-19Influenza, HumanInfluenza VaccinesEuropeHumansPandemicsPrimary Health CareSentinel SurveillanceInfluenza VaccinesCOVID-19EuropeInfluenza-Like Illness (ILI)primary careSARS-CoV-2Sentinel surveillance

Identifiers

PMID35775429
PMCPMC9248262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.